title: Citrobacter koseri cellulitis during anti-CD20 monoclonal antibody (ofatumumab) treatment for B-cell chronic lymphocytic leukaemia.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Kluger
authors.forename: Guillaume
authors.initials: G
authors.lastname: Cartron
authors.forename: Didier
authors.initials: D
authors.lastname: Bessis
authors.forename: Bernard
authors.initials: B
authors.lastname: Guillot
authors.forename: Céline
authors.initials: C
authors.lastname: Girard
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002481:Cellulitis / Q000139:chemically induced* / Q000188:drug therapy / Q000382:microbiology / Q000473:pathology; D041041:Citrobacter koseri / Q000302:isolation & purification*; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D008875:Middle Aged; D012867:Skin / Q000382:microbiology / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C527517:ofatumumab